Global Squamous Cell Carcinoma Of The Head And Neck Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 12.00 Billion |
 Market Size (Forecast Year) |
USD 24.80 Billion |
 CAGR |
% |
| Major Markets Players |
|
全球头颈部鳞状细胞癌治疗市场，按药物类别（免疫疗法、化疗、靶向疗法）、类型（唾液腺、口腔和口咽、鼻腔和鼻旁窦、鼻咽、喉和咽下）、诊断（活检筛查测试、血液测试、牙科诊断、影像学、内窥镜检查）、治疗（放射、手术、化疗、免疫疗法）、治疗类别（PD 抑制剂、EGFR 抑制剂、微管抑制剂、有丝分裂抑制剂）、分销渠道（线上、线下）、最终用户（医院、专科诊所、门诊手术中心）划分 - 行业趋势和预测到 2030 年。
头颈部鳞状细胞癌治疗市场分析及规模
头颈癌发病率的不断上升有望推动市场增长。根据美国临床肿瘤学会 (ASCO) 的数据，在美国，大约 4% 的癌症病例与头颈癌有关。多年来，口服给药途径预计将成为预测期内增长最快的领域，因为用于治疗头颈癌患者的口服治疗药物越来越多。
Data Bridge Market Research 分析，头颈部鳞状细胞癌治疗市场规模将从 2022 年的 120 亿美元增至 2030 年的 248 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 9.50%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
头颈部鳞状细胞癌治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
药物类别（免疫疗法、化疗、靶向疗法）、类型（唾液腺、口腔和口咽、鼻腔和鼻旁窦、鼻咽、喉和咽下）、诊断（活检筛查测试、血液检查、牙科诊断、成像、内窥镜检查）、治疗（放射、手术、化疗、免疫疗法）、治疗类别（PD 抑制剂、EGFR 抑制剂、微管抑制剂、有丝分裂抑制剂）、分销渠道（线上、线下）、最终用户（医院、专科诊所、门诊手术中心） |
|
覆盖国家 |
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Boehringer Ingelheim International GmbH. (Germany), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd (Israel), AbbVie Inc (U.S.), Astellas Pharma Inc. (Japan), Sumitomo Pharma Co., Ltd (Japan), Amgen Inc (U.S.), Curis, Inc (U.S.) |
|
Market Opportunities |
|
Market Definition
Squamous cell carcinoma of the head and neck is the most prevalent form of skin cancer that initiates from the squamous cells in the skin's middle and outer layers. It is caused either by long exposure to harmful ultraviolet (UV) radiation or maybe for other idiopathic reasons. The squamous cell carcinoma of the head and neck treatment deals with the treatment process of the disease by surgery, radiation, chemotherapy, or immunotherapy.
Global Squamous Cell Carcinoma of the Head and Neck Treatment Market Dynamics
Drivers
- Increasing R&D for Cancer Drugs and Treatment
Head and neck cancers are mostly treated by single or combination therapies. Healthcare providers are continuously developing drugs and treatments for treating the disease due to the presence of varied types of head and neck cancers. Presently, numerous cancer vaccines for treating head and cancer drugs are under different phases of clinical trials. Pharmaceutical manufacturers are investing a lot in research and development to cure the disease properly. The Food and Drug Administration (FDA) has approved numerous drugs for treating head and neck cancer. This factor leads to the growth of the market.
- Increasing Adoption of Immune Therapeutics
Immune therapeutics or immunotherapy is offered to cancer patients as it holds various benefits over other therapy types. With the increasing concern for the growing number of cancer cases, there is an increasing need to treat these patients. Immunotherapy is widely used in these patients as it helps the body prevent cancer with its natural defenses. Thus, this factor help in the market growth.
Opportunities
- Increasing Demand for Injectable Administration
The huge growth of injectable route of administration increases the market growth. This can be due to the huge availability of HNC therapeutic drugs in injectable form, better availability, and increased efficiency of injectable drugs. There are a huge number of drugs that are available in injectable form. For instance, Keytruda, manufactured by Merck & Co., Inc., is administered intravenously as an infusion in patients suffering from head and neck cancer. Thus, this factor boosts market growth.
- Increasing Strategic Developments Associated with Squamous Cell Carcinoma of the Head and Neck Treatment
Market players are adopting various strategies for market growth, such as mergers and acquisitions. For instance, Sanofi acquired Amunix Pharmaceuticals, Inc. at USD 1 billion in 2021. This acquisition boosts the company's oncology product portfolio and provides a high-growth opportunity. Therefore, this factor acts as a major factor that increases market growth.
Restraints/Challenges
- High Cost of Head and Neck Treatment Drugs
Treating this cancer is very costly, particularly for individuals from -low and -middle-income groups. Furthermore, the unavailability of proper healthcare standards in numerous nations is also expected to decrease the demand for head and neck squamous cell carcinoma (HNSCC) treatment and drugs. The increasing cost of treatment and drugs is anticipated to impede market growth during the forecast period.
This squamous cell carcinoma of the head and neck treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the squamous cell carcinoma of the head and neck treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2021, the U.S. FDA granted the breakthrough therapy designation for Tipifarnib, developed by Kura Oncology, Inc., for treating patients suffering from head and neck squamous cell carcinoma (HNSCC). This is a selective, potent, and orally administered drug.
Global Squamous Cell Carcinoma of the Head and Neck Treatment Market Scope
The squamous cell carcinoma of the head and neck treatment market is segmented on the basis of drug class, type, diagnosis, treatment, therapeutic class distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Immunotherapy
- Chemotherapy
- Targeted Therapy
Type
- Salivary Gland
- Oral and Oropharyngeal
- Nasal Cavity and Paranasal Sinus
- Nasopharyngeal
- Laryngeal
- Hypo Pharyngeal
Diagnosis
- Bioscopy Screening Tests
- Blood Tests
- Dental Diagnosis
- Imaging
- Endoscopy
Treatment
- Radiation
- Surgery
- Chemotherapy
- Immunotherapy
Therapeutic Class
- PD Inhibitors
- EGFR Inhibitors
- Microtubule Inhibitors
- Mitotic Inhibitors
Distribution Channel
- Online
- Offline
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
Squamous Cell Carcinoma of the Head and Neck Treatment Market Regional Analysis/Insights
The squamous cell carcinoma of the head and neck treatment market is analyzed and market size insights and trends are provided by drug class, type, diagnosis, treatment, therapeutic class distribution channel and end user as referenced above.
The countries covered in the squamous cell carcinoma of the head and neck treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the forecast period the squamous cell carcinoma of the head and neck treatment market because of the growing population, lifestyle, and adoption of advanced technologies. The growing elderly populations and growing prescription of immunotherapy drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) used to treat numerous types of HNC are anticipated to boost the market growth in upcoming years.
North America dominates the market in the forecast period because of the growing levels of investment in developing advanced technologies such as platinum-based therapy in this region. Also, government support for the development of the healthcare sector is helping in the market growth.
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
头颈部鳞状细胞癌治疗市场还为您提供了每个国家/地区资本设备医疗支出增长的详细市场分析、头颈部鳞状细胞癌治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对头颈部鳞状细胞癌治疗市场的影响。数据适用于 2011-2021 年的历史时期。
竞争格局和头颈部鳞状细胞癌治疗市场份额分析
头颈部鳞状细胞癌治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对头颈部鳞状细胞癌治疗市场的关注有关。
头颈部鳞状细胞癌治疗市场的一些主要参与者包括：
- 赛诺菲（法国）
- F. Hoffmann-La Roche Ltd.（瑞士）
- 勃林格殷格翰国际有限公司（德国）
- 葛兰素史克公司 (英国)
- 诺华公司（瑞士）
- 拜耳公司（德国）
- 礼来（美国）
- 默克公司（美国）
- 阿斯利康（英国）
- 强生私人有限公司（美国）
- Cipla Inc.（美国）
- 雅培（美国）
- AbbVie Inc.（美国）
- 太阳制药工业有限公司 (印度)
- 梯瓦制药工业有限公司 (以色列)
- AbbVie Inc（美国）
- 安斯泰来制药有限公司 (日本)
- 住友制药株式会社（日本）
- 安进公司 (美国)
- Curis, Inc（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
